Just a collection of links for information, for TCS members and their vets.
UC Davis used S boulardii to treat a cat infected with what they thought was antibiotic-resistant clostridium difficile because the owner could not afford vancomycin. After one month, the cat tested negative for C. diff.
Madewell et al. 1999. "Clostridium difficile: A survey of fecal carriage in cats in a veterinary medical teaching hospital," J VET diagn Invest 11:50-54 The discussion of S boulardii is on p. 53. http://vdi.sagepub.com/content/11/1/50.full.pdf
Simply explained in the Biocodex FDA submission (last link), S boulardii is not digested and absorbed in the gut and does not exert its effect systemically. Instead, S boulardii acts locally in the lumen of the gut. During its passage through the intestine, S boulardii mimics the physiological effects of the digestive flora, stimulating healthy immune response and reducing inflammation.
Saccharomyces boulardii prevents enteritis from Clostridium difficile infection http://archives.focus.hms.harvard.edu/2006/091506/research_briefs.shtml
"Saccharomyces boulardii in Gastrointestinal Related Disorders," Point Institute Technical Report (2008) http://www.pointinstitute.org/wp-co...s-Boulardii-in-GI-related-disorders-paper.pdf
Saccharomyces boulardii effects on gastrointestinal diseases, (Zanello et al. 2009) http://www.horizonpress.com/cimb/v/v11/47.pdf
Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii, (Pothoulakis 2009) http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04102.x/pdf
"Systematic review and meta-analysis of Saccharomyces boulardii in adult patients," (McFarland 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868213/
Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis, (Thomas et al. 2011) http://ajpgi.physiology.org/content/ajpgi/301/6/G1083.full.pdf
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders, (Kelesidis & Pothoulakis 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296087/pdf/10.1177_1756283X11428502.pdf
New Dietary Ingredient Notification for S boulardii (FDA submission) by Biocodex (Florastor) (includes summary table and references) http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0301-04-vol239.pdf
UC Davis used S boulardii to treat a cat infected with what they thought was antibiotic-resistant clostridium difficile because the owner could not afford vancomycin. After one month, the cat tested negative for C. diff.
Madewell et al. 1999. "Clostridium difficile: A survey of fecal carriage in cats in a veterinary medical teaching hospital," J VET diagn Invest 11:50-54 The discussion of S boulardii is on p. 53. http://vdi.sagepub.com/content/11/1/50.full.pdf
Simply explained in the Biocodex FDA submission (last link), S boulardii is not digested and absorbed in the gut and does not exert its effect systemically. Instead, S boulardii acts locally in the lumen of the gut. During its passage through the intestine, S boulardii mimics the physiological effects of the digestive flora, stimulating healthy immune response and reducing inflammation.
Saccharomyces boulardii prevents enteritis from Clostridium difficile infection http://archives.focus.hms.harvard.edu/2006/091506/research_briefs.shtml
"Saccharomyces boulardii in Gastrointestinal Related Disorders," Point Institute Technical Report (2008) http://www.pointinstitute.org/wp-co...s-Boulardii-in-GI-related-disorders-paper.pdf
Saccharomyces boulardii effects on gastrointestinal diseases, (Zanello et al. 2009) http://www.horizonpress.com/cimb/v/v11/47.pdf
Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii, (Pothoulakis 2009) http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04102.x/pdf
"Systematic review and meta-analysis of Saccharomyces boulardii in adult patients," (McFarland 2010) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2868213/
Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis, (Thomas et al. 2011) http://ajpgi.physiology.org/content/ajpgi/301/6/G1083.full.pdf
Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders, (Kelesidis & Pothoulakis 2012) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296087/pdf/10.1177_1756283X11428502.pdf
New Dietary Ingredient Notification for S boulardii (FDA submission) by Biocodex (Florastor) (includes summary table and references) http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0301-04-vol239.pdf